Show simple item record

dc.contributor.authorSpain, L
dc.contributor.authorWalls, G
dc.contributor.authorMessiou, C
dc.contributor.authorTurajlic, S
dc.contributor.authorGore, M
dc.contributor.authorLarkin, J
dc.date.accessioned2017-03-24T14:30:36Z
dc.date.issued2017-01
dc.identifier.citationCancer immunology, immunotherapy : CII, 2017, 66 (1), pp. 113 - 117
dc.identifier.issn0340-7004
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/503
dc.identifier.eissn1432-0851
dc.identifier.doi10.1007/s00262-016-1926-2
dc.description.abstractBackground The efficacy and potential toxicity of rechallenge with combination ipilimumab and nivolumab has not been described. Retreatment of patients with immune checkpoint inhibitors in the setting of prior significant toxicity lacks evidence-based guidance.Methods We present the first three, consecutive patients who received re-treatment with combination ipilimumab and nivolumab for metastatic melanoma managed at our institution.Results Rechallenge with combination ipilimumab and nivolumab in the setting of prior grade 3 toxicity with initial combination therapy is feasible, and responses are seen. We highlight the fact that grade 3 toxicity is likely to recur, but if so, can be manageable.Conclusions Retreatment with ipi + nivo may be considered an option in carefully selected, well-informed patients. More research is required to delineate the benefits and risks with this approach.
dc.formatPrint-Electronic
dc.format.extent113 - 117
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectMelanoma
dc.subjectNeoplasm Metastasis
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectAntibodies, Monoclonal
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectIpilimumab
dc.subjectNivolumab
dc.titleEfficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series.
dc.typeJournal Article
dcterms.dateAccepted2016-11-06
rioxxterms.versionofrecord10.1007/s00262-016-1926-2
rioxxterms.licenseref.startdate2017-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCancer immunology, immunotherapy : CII
pubs.issue1
pubs.notes12 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume66
pubs.embargo.terms12 months
icr.researchteamMelanoma and Kidney Canceren_US
dc.contributor.icrauthorGore, Martinen
dc.contributor.icrauthorLarkin, Jamesen
dc.contributor.icrauthorMessiou, Christinaen
dc.contributor.icrauthorMarsden,en
dc.contributor.icrauthorTurajlic, Samraen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record